Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.

Florence CoussyR El BottyM LavigneC GuL FuhrmannA BriauxL de KoningA DahmaniE MontaudonL MorissetL HuguetL SourdP PainsecS Chateau-JoubertT LarcherS VacherS MelaabiA Vincent SalomonE MarangoniI Bieche

Published in: Journal of hematology & oncology (2020)

The treatment of metaplastic breast cancer PDXs by activation of the PI3K-AKT-mTOR and RTK-MAPK pathways at the genomic and protein levels with a combination of PI3K and MEK inhibitors resulted in tumor regression in mutated models and may therefore be of interest for therapeutic purposes.

Keyphrases

pi k akt
signaling pathway
oxidative stress
disease activity
protein protein
wild type
copy number
rheumatoid arthritis
systemic lupus erythematosus
ulcerative colitis
breast cancer risk